Non-Dopaminergic Treatments for Motor Control in Parkinson’s Disease: An Update
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Non-Dopaminergic Treatments for Motor Control in Parkinson’s Disease: An Update
Authors
Keywords
-
Journal
CNS DRUGS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-08-12
DOI
10.1007/s40263-020-00754-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease
- (2020) Clarissa A. Pisanò et al. NEUROPHARMACOLOGY
- Safety and Efficacy of Levetiracetam for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson`s Disease: A Systematic Review
- (2019) Mahmoud Ahmed Ebada et al. CNS & Neurological Disorders-Drug Targets
- Efficacy of istradefylline for gait disorders with freezing of gait in Parkinson’s disease: A single-arm, open-label, prospective, multicenter study
- (2019) Mutsumi Iijima et al. EXPERT OPINION ON PHARMACOTHERAPY
- Nicotine Bitartrate Reduces Falls and Freezing of Gait in Parkinson Disease: A Reanalysis
- (2019) Abraham Lieberman et al. Frontiers in Neurology
- Pathophysiological clues to therapeutic applications of glutamate mGlu5 receptor antagonists in levodopa-induced dyskinesia
- (2019) Shayan Pourmirbabaei et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- CLINICAL TRIAL HIGHLIGHTS – DYSKINESIA
- (2019) Kevin McFarthing et al. Journal of Parkinsons Disease
- Add-on Drug Approved for “Off” Episodes of Parkinson Disease
- (2019) Rebecca Voelker JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Quadruple Decision Making for Parkinson’s Disease Patients: Combining Expert Opinion, Patient Preferences, Scientific Evidence, and Big Data Approaches to Reach Precision Medicine
- (2019) Lieneke van den Heuvel et al. Journal of Parkinsons Disease
- Effects of augmenting cholinergic neurotransmission on balance in Parkinson's disease
- (2019) Martina Mancini et al. PARKINSONISM & RELATED DISORDERS
- Bradykinesia Is Driven by Cumulative Beta Power During Continuous Movement and Alleviated by Gabaergic Modulation in Parkinson's Disease
- (2019) Emma J. Prokic et al. Frontiers in Neurology
- A Randomized Trial of Oral and Transdermal Rivastigmine for Postural Instability in Parkinson Disease Dementia
- (2018) Jaime McDonald et al. CLINICAL NEUROPHARMACOLOGY
- Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson’s Disease
- (2018) Lawrence W. Elmer et al. CNS DRUGS
- International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease
- (2018) Susan H. Fox et al. MOVEMENT DISORDERS
- The nature of postural tremor in Parkinson disease
- (2018) Michiel F. Dirkx et al. NEUROLOGY
- Repurposing drugs to treat l -DOPA-induced dyskinesia in Parkinson's disease
- (2018) Tom H. Johnston et al. NEUROPHARMACOLOGY
- A new outlook on cholinergic interneurons in Parkinson’s disease and L-DOPA-induced dyskinesia
- (2018) Melissa M. Conti et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- Different generations of type-B monoamine oxidase inhibitors in Parkinson’s disease: from bench to bedside
- (2018) Marika Alborghetti et al. Current Neuropharmacology
- An mGlu4-Positive Allosteric Modulator Alleviates Parkinsonism in Primates
- (2018) Delphine Charvin et al. MOVEMENT DISORDERS
- A randomized, controlled pilot study of the effects of vitamin D supplementation on balance in Parkinson's disease: Does age matter?
- (2018) Amie L. Hiller et al. PLoS One
- Beyond Dopamine: GABA, Glutamate, and the Axial Symptoms of Parkinson Disease
- (2018) Ruth L. O'Gorman Tuura et al. Frontiers in Neurology
- Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques
- (2018) Tom H. Johnston et al. MOVEMENT DISORDERS
- Drug repurposing: progress, challenges and recommendations
- (2018) Sudeep Pushpakom et al. NATURE REVIEWS DRUG DISCOVERY
- Naftazone in advanced Parkinson's disease: An acute L-DOPA challenge randomized controlled trial
- (2018) Jean-Christophe Corvol et al. PARKINSONISM & RELATED DISORDERS
- Parkinson Diseases in the 2020s and Beyond: Replacing Clinico-Pathologic Convergence With Systems Biology Divergence
- (2018) Alberto J. Espay et al. Journal of Parkinsons Disease
- High-dose transdermal nicotine in Parkinson's disease patients: a randomized, open-label, blinded-endpoint evaluation phase 2 study
- (2017) G. Villafane et al. EUROPEAN JOURNAL OF NEUROLOGY
- Dalfampridine in Parkinson's disease related gait dysfunction: A randomized double blind trial
- (2017) Corneliu C. Luca et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study
- (2017) Christopher G. Goetz et al. MOVEMENT DISORDERS
- Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease
- (2017) Susan H. Fox et al. MOVEMENT DISORDERS
- Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3)
- (2017) Wolfgang Oertel et al. MOVEMENT DISORDERS
- Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease
- (2017) Fabrizio Stocchi et al. NEUROLOGY
- Caffeine as symptomatic treatment for Parkinson disease (Café-PD)
- (2017) Ronald B. Postuma et al. NEUROLOGY
- Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations
- (2017) Anthony H. V. Schapira et al. JAMA Neurology
- ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study)
- (2017) Rajesh Pahwa et al. JAMA Neurology
- Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial
- (2016) Emily J Henderson et al. LANCET NEUROLOGY
- Mavoglurant in Parkinson's patients withl-Dopa-induced dyskinesias: Two randomized phase 2 studies
- (2016) Claudia Trenkwalder et al. MOVEMENT DISORDERS
- A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia
- (2016) Claudia Trenkwalder et al. MOVEMENT DISORDERS
- A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease
- (2016) François Tison et al. MOVEMENT DISORDERS
- Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesias
- (2016) Tanuja Bordia et al. NEUROBIOLOGY OF DISEASE
- Histamine and the striatum
- (2016) J. Paul Bolam et al. NEUROPHARMACOLOGY
- Adjunctive preladenant: A placebo-controlled, dose-finding study in Japanese patients with Parkinson's disease
- (2016) Nobutaka Hattori et al. PARKINSONISM & RELATED DISORDERS
- Cost-effectiveness of droxidopa in patients with neurogenic orthostatic hypotension: post-hoc economic analysis of Phase 3 clinical trial data
- (2016) Clément François et al. JOURNAL OF MEDICAL ECONOMICS
- Memantine and reduced time with dyskinesia in Parkinson′s Disease
- (2015) K. Wictorin et al. ACTA NEUROLOGICA SCANDINAVICA
- Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study
- (2015) Per Svenningsson et al. BRAIN
- A Long-Term Study of Istradefylline Safety and Efficacy in Patients With Parkinson Disease
- (2015) Tomoyoshi Kondo et al. CLINICAL NEUROPHARMACOLOGY
- Impact of Rivastigmine on Cognitive Dysfunction and Falling in Parkinson's Disease Patients
- (2015) Zhenguang Li et al. EUROPEAN NEUROLOGY
- Gait and attentional performance in freezers under methylphenidate
- (2015) A. Delval et al. GAIT & POSTURE
- Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients
- (2015) Rajeev Kumar et al. INTERNATIONAL JOURNAL OF NEUROSCIENCE
- Zonisamide improves wearing-off in Parkinson's disease: A randomized, double-blind study
- (2015) Miho Murata et al. MOVEMENT DISORDERS
- New treatments for levodopa-induced motor complications
- (2015) Olivier Rascol et al. MOVEMENT DISORDERS
- α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage
- (2015) Danhui Zhang et al. MOVEMENT DISORDERS
- Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study)
- (2015) Rajesh Pahwa et al. MOVEMENT DISORDERS
- Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and l-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist
- (2015) Hanna Iderberg et al. NEUROPHARMACOLOGY
- A randomized, double-blind, controlled trial of add-on therapy in moderate-to-severe Parkinson's disease
- (2015) Shifu Zhao et al. PARKINSONISM & RELATED DISORDERS
- Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease
- (2015) Robert A. Hauser et al. JAMA Neurology
- Levetiracetam Ameliorates L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats Inducing Critical Molecular Changes in the Striatum
- (2015) Huan Du et al. Parkinsons Disease
- Efficacy of Adenosine A2A Receptor Antagonist Istradefylline as Augmentation for Parkinson’s Disease: A Meta-analysis of Randomized Controlled Trials
- (2014) Yingqun Tao et al. CELL BIOCHEMISTRY AND BIOPHYSICS
- Adenosine A2A Receptor Antagonists in Parkinson’s Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued
- (2014) Annalisa Pinna CNS DRUGS
- Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial
- (2014) Robert A Hauser et al. LANCET NEUROLOGY
- Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease
- (2014) Rupam Borgohain et al. MOVEMENT DISORDERS
- Norepinephrine deficiency in Parkinson's disease: The case for noradrenergic enhancement
- (2014) Alberto J. Espay et al. MOVEMENT DISORDERS
- Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology
- (2014) B. S. Koppel et al. NEUROLOGY
- Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease
- (2014) Christopher Kobylecki et al. PARKINSONISM & RELATED DISORDERS
- AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys
- (2014) Thérèse Di Paolo et al. PARKINSONISM & RELATED DISORDERS
- Non-dopaminergic Treatments for Motor Control in Parkinson’s Disease
- (2013) Susan H. Fox DRUGS
- Intravenous amantadine on freezing of gait in Parkinson’s disease: a randomized controlled trial
- (2013) Jee Young Lee et al. JOURNAL OF NEUROLOGY
- Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations
- (2013) Rupam Borgohain et al. MOVEMENT DISORDERS
- Adenosine A2Areceptor antagonist istradefylline reduces daily OFF time in Parkinson's disease
- (2013) Yoshikuni Mizuno et al. MOVEMENT DISORDERS
- AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study
- (2013) Fabrizio Stocchi et al. MOVEMENT DISORDERS
- Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia
- (2013) Erwan Bezard et al. MOVEMENT DISORDERS
- Withdrawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trial
- (2013) F. Ory-Magne et al. NEUROLOGY
- The serotonergic system in motor and non-motor manifestations of Parkinson’s disease
- (2013) Philippe Huot et al. EXPERIMENTAL BRAIN RESEARCH
- Targeting Glutamate Receptors to Tackle the Pathogenesis, Clinical Symptoms and Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease
- (2012) Susan Duty CNS DRUGS
- Emerging therapies for Parkinsonʼs disease
- (2012) Werner Poewe et al. CURRENT OPINION IN NEUROLOGY
- Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study
- (2012) C. Moreau et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Amantadine improves gait in PD patients with STN stimulation
- (2012) Hiu-Fai Chan et al. PARKINSONISM & RELATED DISORDERS
- Intravenous Amantadine for Freezing of Gait Resistant to Dopaminergic Therapy: A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Clinical Trial
- (2012) Young Eun Kim et al. PLoS One
- Norepinephrine: the next therapeutics frontier for Parkinson's disease
- (2012) Peter A LeWitt Translational Neurodegeneration
- A proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson’s disease
- (2011) Olivier Rascol et al. FUNDAMENTAL & CLINICAL PHARMACOLOGY
- Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial
- (2011) Robert A Hauser et al. LANCET NEUROLOGY
- Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease
- (2011) Christopher Kobylecki et al. MOVEMENT DISORDERS
- AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials
- (2011) Daniela Berg et al. MOVEMENT DISORDERS
- Effect of intravenous amantadine on dopaminergic-drug-resistant freezing of gait
- (2011) Young Eun Kim et al. PARKINSONISM & RELATED DISORDERS
- Istradefylline for Parkinson's disease patients experiencing motor fluctuations: Results of the KW-6002-US-018 study
- (2011) Emmanuelle Pourcher et al. PARKINSONISM & RELATED DISORDERS
- Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap
- (2010) Paolo Calabresi et al. LANCET NEUROLOGY
- Effect of histamine H2receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease
- (2010) Tom H. Johnston et al. MOVEMENT DISORDERS
- Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway
- (2009) S. Yamamura et al. NEUROPHARMACOLOGY
- The Unified Dyskinesia Rating Scale: Presentation and clinimetric profile
- (2008) Christopher G. Goetz et al. MOVEMENT DISORDERS
- Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results
- (2008) Christopher G. Goetz et al. MOVEMENT DISORDERS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search